A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase.


Mitomycin C (MMC) is a chemotherapeutic drug that requires an enzymatic bioreduction to exert its biological effects. Upon reduction, MMC is converted into a highly reactive bis-electrophilic intermediate that alkylates cellular nucleophiles. Alkylation of DNA is the most favored mechanism of action for MMC, but other modes of action, such as redox cycling… (More)
DOI: 10.1021/tx3002065


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics